Doctor of Osteopathy Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

James Stafford

Neurology Jupiter, FL Doctor of Osteopathy

NPI 1457389058 CMS profile 202485

601 University Blvd, Suite 102 101, Jupiter, FL 33458

Open in the dashboard

General payments

$11,047

608 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, James Stafford of Jupiter, FL is reported in the CMS Open Payments database as having received $11,047 across 608 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $180 5
2021 General $4,054 229
2020 General $2,892 163
2019 General $3,920 211

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Stafford
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to James Stafford were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year James Stafford Neurology median Middle half National median
2019 $3,920 $474 $118–$2,177 $163
2020 $2,892 $367 $82–$2,309 $114
2021 $4,054 $438 $104–$2,547 $132
2022 $180 $442 $103–$2,388 $149
2023 $0 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Novartis Pharmaceuticals Corporation $855 53 payments
  2. Biogen, Inc. $674 35 payments
  3. Allergan Inc. $651 51 payments
  4. Genzyme Corporation $611 27 payments
  5. UCB, Inc. $574 31 payments
  6. EMD Serono, Inc. $555 29 payments
  7. AbbVie, Inc. $544 35 payments
  8. Adamas Pharmaceuticals, Inc. $544 31 payments
  9. Teva Pharmaceuticals USA, Inc. $471 20 payments
  10. Acorda Therapeutics, Inc $459 20 payments
  11. Other $5,109 276 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $10,608 584 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $313 17 payments
  3. Education $126 7 payments
Products named General payments · program years 2019–2022
  1. AIMOVIG $629 36 payments
  2. GOCOVRI $544 31 payments
  3. BOTOX $494 39 payments
  4. INBRIJA $459 20 payments
  5. UBRELVY $411 27 payments
  6. KESIMPTA $371 23 payments
  7. RYTARY $357 16 payments
  8. Briviact $352 16 payments
  9. EMGALITY $346 18 payments
  10. NORTHERA $324 20 payments
  11. Other $7,588 429 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

608 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record